RDDT Deadline: Rosen Law Firm Urges Reddit, Inc. (NYSE: RDDT) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
RAK ICC Strengthens Foundations Regime with 2025 Legislative Enhancements
WL Delicious Announced 2025 Interim Results
Kovo+ Holdings Inc. Secures Lead Order and Strategic Financing Commitments
Soluna Reports Q2’25 Results
YAVNE, Israel, Sept. 11, 2023 (GLOBE NEWSWIRE) — MediWound Ltd. (Nasdaq: MDWD) (“MediWound”), a fully integrated biopharmaceutical…
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Sept. 11, 2023 (GLOBE NEWSWIRE) — eFFECTOR Therapeutics,…
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Sept. 11, 2023 (GLOBE NEWSWIRE) — eFFECTOR Therapeutics,…
Data from Phase 3 Trial of NE3107 Presented as Poster at the 148th American Neurological…
Data from Phase 3 Trial of NE3107 Presented as Poster at the 148th American Neurological…
FDA Acceptance of Libervant™ (diazepam) Buccal Film NDA for treatment of seizure clusters in patients…
FDA Acceptance of Libervant™ (diazepam) Buccal Film NDA for treatment of seizure clusters in patients…
WALTHAM, Mass., Sept. 11, 2023 (GLOBE NEWSWIRE) — Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company…
WALTHAM, Mass., Sept. 11, 2023 (GLOBE NEWSWIRE) — Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company…
JERUSALEM, Sept. 11, 2023 (GLOBE NEWSWIRE) — via IBN — Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI),…
JERUSALEM, Sept. 11, 2023 (GLOBE NEWSWIRE) — via IBN — Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI),…
Initial primary endpoint data anticipated in late 2023 or early Q1 2024 WALTHAM, Mass., Sept….
Initial primary endpoint data anticipated in late 2023 or early Q1 2024 WALTHAM, Mass., Sept….
AUSTIN, Texas, Sept. 11, 2023 (GLOBE NEWSWIRE) — Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a…
AUSTIN, Texas, Sept. 11, 2023 (GLOBE NEWSWIRE) — Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a…
—Overall response rates of 12.5% are observed in the enobosarm group in a heavily pretreated…
—Overall response rates of 12.5% are observed in the enobosarm group in a heavily pretreated…
– Interim analysis of masked data shows EYP-1901 is well tolerated with no reported drug-related…
– Interim analysis of masked data shows EYP-1901 is well tolerated with no reported drug-related…